NASDAQ:XLRNAcceleron Pharma Stock Price, Forecast & News

Acceleron Pharma's stock was trading at $84.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, XLRN shares have increased by 8.5% and is now trading at $91.54. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 1 sell rating, 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Acceleron Pharma.

Acceleron Pharma is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Acceleron Pharma.

Acceleron Pharma Inc (NASDAQ:XLRN) announced its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by $0.09. The biopharmaceutical company had revenue of $4.30 million for the quarter, compared to the consensus estimate of $5.26 million. Acceleron Pharma had a negative return on equity of 30.14% and a negative net margin of 182.31%. The firm's revenue was up 53.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.74) earnings per share. View Acceleron Pharma's earnings history.

13 brokerages have issued 12-month price targets for Acceleron Pharma's shares. Their forecasts range from $71.00 to $137.00. On average, they expect Acceleron Pharma's share price to reach $111.92 in the next twelve months. This suggests a possible upside of 22.3% from the stock's current price. View analysts' price targets for Acceleron Pharma.

Press coverage about XLRN stock has trended very negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Acceleron Pharma earned a news sentiment score of -3.7 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutAcceleron Pharma.

Acceleron Pharma saw a increase in short interest in April. As of April 30th, there was short interest totaling 4,080,000 shares, an increase of 7.4% from the April 15th total of 3,800,000 shares. Based on an average trading volume of 734,300 shares, the days-to-cover ratio is presently 5.6 days. Currently, 8.9% of the company's stock are short sold. View Acceleron Pharma's Current Options Chain.

Some companies that are related to Acceleron Pharma include NOVOZYMES A/S/S (NVZMY), BioNTech (BNTX), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), argenx (ARGX), Repligen (RGEN), Allogene Therapeutics (ALLO), Adaptive Biotechnologies (ADPT), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF) and bluebird bio (BLUE). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Incyte (INCY), Intel (INTC), NVIDIA (NVDA), Bausch Health Companies (BHC), Cisco Systems (CSCO), LogicBio Therapeutics (LOGC), Corcept Therapeutics (CORT) and FibroGen (FGEN).

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Acceleron Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.56%), Wellington Management Group LLP (3.61%), State Street Corp (2.76%), TimesSquare Capital Management LLC (1.87%), Cormorant Asset Management LP (1.53%) and Geode Capital Management LLC (1.28%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Ravindra Kumar and Sujay Kango. View institutional ownership trends for Acceleron Pharma.

XLRN stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Bank of New York Mellon Corp, Eagle Asset Management Inc., Carillon Tower Advisers Inc., Foresite Capital Management III LLC, Foresite Capital Management II LLC, TimesSquare Capital Management LLC, and QVT Financial LP. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, Jean George, John D Quisel, Kevin F Mclaughlin, Ravindra Kumar, and Sujay Kango. View insider buying and selling activity for Acceleron Pharma.

XLRN stock was acquired by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Lord Abbett & CO. LLC, BlackRock Inc., Nuveen Asset Management LLC, Orbimed Advisors LLC, Eventide Asset Management LLC, Invesco Ltd., and Two Sigma Investments LP. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene, and Joseph S Zakrzewski. View insider buying and selling activity for Acceleron Pharma.

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XLRN stock can currently be purchased for approximately $91.54.

Acceleron Pharma has a market capitalization of $4.93 billion and generates $73.99 million in revenue each year. The biopharmaceutical company earns $-124,860,000.00 in net income (profit) each year or ($2.38) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe.

The official website for Acceleron Pharma is www.acceleronpharma.com.

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]